FrancophonIA/ELRC3.0 huggingface dataset:
English: INTELENCE can be co-administered with H2-receptor antagonists without dose adjustments.
Croatian: INTELENCE se može primjenjivati istodobno s antagonistima receptora H2 bez prilagodbe doze.
English: Blood and lymphatic system disorders common thrombocytopaenia, anaemia, decreased neutrophils uncommon decreased white blood cell count
Croatian: Poremećaji krvi i limfnog sustava često trombocitopenija, anemija, sniženi neutrofili manje često snižen broj bijelih krvnih stanica
English: Population pharmacokinetic analysis of the DUET-1 and DUET-2 trials showed reduced clearance (potentially leading to increased exposure and alteration of the safety profile) for etravirine in HIV-1 infected patients with hepatitis B and/or hepatitis C virus co-infection.
Croatian: Istodobna infekcija virusom hepatitisa B i/ili hepatitisa C Populacijska analiza farmakokinetike ispitivanja DUET-1 i DUET-2 pokazala je smanjeni klirens (što potencijalno vodi do povišene izloženosti i promjene profila sigurnosti) etravirina kod HIV-1 zaraženih bolesnika s koinfekcijom virusa hepatitisa B i/ili hepatitisa C.
English: The frequency rate of the side effects associated with INTELENCE is given below.
Croatian: Stopa učestalosti nuspojava povezanih s lijekom INTELENCE navedena je niže.
English: Baseline HIV-1 RNA < 30,000 copies/ml ≥ 30,000 and < 100,000 copies/ml ≥ 100,000 copies/ml Baseline CD4 count (x 10
Croatian: Početne vrijednosti HIV-1 RNK < 30.000 kopija/ml ≥ 30.000 i < 100.000 kopija/ml ≥ 100.000 kopija/ml
English: Therefore, INTELENCE is not recommended in patients with severe hepatic impairment (see sections 4.4 and 5.2).
Croatian: Stoga se INTELENCE ne preporučuje u bolesnika s teškim oštećenjem jetre (vidjeti dio 4.4 i 5.2).
English: (based on AUC) to etravirine were 0.6-fold (mice) and between 0.2- and 0.7-fold (rats), relative to those observed in humans at the recommended therapeutic dose (200 mg twice daily).
Croatian: Pri najvećim ispitanim dozama, sistemske izloženosti etravirinu (na temelju AUC) bile su 0,6 puta veće (miševi) i između 0,2 i 0,7 puta veće (štakori) u odnosu na one uočene kod ljudi pri preporučenoj terapijskoj dozi (200 mg dva puta dnevno).
English: INTELENCE contains lactose
Croatian: INTELENCE sadrži laktozu
English: The recommended dose of INTELENCE is two tablets twice a day.
Croatian: Preporučena doza lijeka INTELENCE su dvije tablete dva puta dnevno.
English: Rash was most frequently mild to moderate, generally macular to maculopapular or erythematous, mostly occurred in the second week of therapy, and was infrequent after week 4.
Croatian: Osip je bio najčešće blag do umjeren, obično makularan do makulopapularan ili eritematozan, većinom se javljao u drugom tjednu terapije, a bio je manje učestalosti nakon 4. tjedna.
English: (Hypericum perforatum)
Croatian: Gospina trava (Hypericum perforatum)
English: • HIV-1 plasma viral load > 5,000 HIV-1 RNA copies/ml at screening
Croatian: • opterećenje virusom HIV-1 u plazmi > 5000 HIV-1 RNK kopija/ml na probiru
English: Co-administration with medicinal products primarily metabolised by CYP2C9 or CYP2C19, or transported by P-glycoprotein, may result in increased plasma concentrations of such medicinal products, which could increase or prolong their therapeutic effect or alter their adverse events profile.
Croatian: Istovremena primjena s lijekovima koji se primarno metaboliziraju putem CYP2C9 ili CYP2C19, ili se vežu na P-glikoprotein, može rezultirati povećanim koncentracijama tih lijekova u plazmi, što bi moglo povećati ili produžiti njihov terapijski učinak ili promijeniti profil njihovih nuspojava.
English: Etravirine arms N = 549
Croatian: Skupine etravirina N = 549
English: In a study conducted in rats, there were no effects on mating or fertility at exposure levels equivalent to those in humans at the clinically recommended dose.
Croatian: U ispitivanju provedenom na štakorima nije bilo učinaka na parenje ili plodnost kod razine izloženosti koja je jednaka onoj kod ljudi pri klinički preporučenoj dozi.
English: Recommended dose of etravirine for paediatric patients 6 years to less than 18 years of age Body weight
Croatian: Preporučena doza etravirina za pedijatrijske bolesnike u dobi od 6 godina do manje od 18 godina
English: INTELENCE is expected to decrease plasma concentrations of these antiarrhythmics.
Croatian: Očekuje se da INTELENCE smanjuje koncentracije tih antiaritmika u plazmi.
English: croscarmellose sodium, magnesium stearate and lactose (as monohydrate).
Croatian: umrežena karmelozanatrij, magnezijev stearat i laktoza (u obliku hidrata).
English: Sensitivity of the virus to etravirine at screening was required.
Croatian: Prilikom probira zahtijevala se osjeljivost virusa na etravirin.
English: Confirmed undetectable viral load (< 50 HIV-1 RNA copies/ml) n (%)
Croatian: Potvrđeno nemjerljivo virusno opterećenje (< 50 HIV-1 RNK kopija/ml) n (%)
English: How to store INTELENCE Contents of the pack and other information
Croatian: Kako INTELENCE izgleda i sadržaj pakiranja
English: Etravirine is metabolised by CYP3A4, CYP2C9 and CYP2C19 followed by glucuronidation of the metabolites by uridine diphosphate glucuronosyl transferase (UDPGT).
Croatian: Etravirin metaboliziraju enzimi CYP3A4, CYP2C9 i CYP2C19 nakon čega slijedi glukuronidacija uridin difosfat glukuronil transferazom (UDPGT).
English: The pharmacokinetics of etravirine have not been studied in patients with renal insufficiency.
Croatian: Farmakokinetika etravirina nije proučavana kod bolesnika s bubrežnom insuficijencijom.
English: Co-administration with elbasvir/grazoprevir (see section 4.5).
Croatian: Istodobna primjena lijeka INTELENCE s elbasvirom/grazoprevirom (vidjeti dio 4.5).
English: Virologic responses (ITT - TLOVR), change from baseline in log10 viral load (NC = F), and change from baseline in CD4 percentage and cell count (NC = F) at week 24 in the TMC125-C213 and pooled DUET studies
Croatian: Tablica 6: Virološki odgovori (ITT - TLOVR), promjena u odnosu na početnu vrijednost log10 virološkog opterećenja (NC = F), i u odnosu na početnu vrijednost CD4 postotka i broja stanica (NC = F) u 24. tjednu TMC125-C213 i udruženih DUET ispitivanja
English: As a precaution it is recommended that concomitant use of etravirine and clopidogrel should be discouraged.
Croatian: Kao mjera opreza, ne preporučuje se istodobna primjena etravirina i klopidogrela.
English: A subgroup analysis of the virologic response (defined as a viral load < 50 HIV-1 RNA copies/ml) at week 48 by baseline viral load and baseline CD4 count (pooled DUET data) is presented in table 4.
Croatian: Analiza virološkog odgovora podskupina (definiranog kao virusno opterećenje < 50 HIV-1 RNK kopija/ml) u 48. tjednu na temelju početnog virusnog opterećenja i početnog broja CD4 stanica (udruženi podaci ispitivanja DUET) prikazani su u tablici 4.
English: Table 5: Proportion of subjects with < 50 HIV-1 RNA copies/ml at week 48 by baseline number of etravirine RAMs in the non-viral failure excluded population of pooled DUET-1 and DUET-2 trials Baseline number of Etravirine RAMs*
Croatian: Tablica 5: Udio ispitanika s < 50 HIV-1 RNK kopija/ml u 48. tjednu prema početnom broju mutacija povezanih s rezistencijom (RAM) na etravirin u populaciji iz koje nisu isključeni ispitanici s virološkim neuspjehom prema združenim podacima ispitivanja DUET-1 i DUET-2 Početni broj RAM za etravirin*
English: In all the other trials conducted with etravirine in HIV-1 infected patients, the following mutations emerged most commonly: L100I, E138G, V179F, V179I, Y181C and H221Y.
Croatian: U svim drugim ispitivanjima provedenima s etravirinom u bolesnika zaraženih virusom HIV-1, najčešće su se javljale sljedeće mutacije: L100I, E138G, V179F, V179I, Y181C i H221Y.
English: The median baseline plasma HIV-1 RNA was 3.9 log10 copies/ml, and the median baseline CD4 cell count was 385 x 10
Croatian: Medijan početne vrijednosti HIV-1 RNK u plazmi bio je 3,9 log10 kopija/ml, a medijan početnog broja CD4 stanica bio je 385 x 10
English: Note: Imputations according to the TLOVR algorithm (TLOVR = Time to Loss of Virologic Response)
Croatian: Napomena: Pripisane vrijednosti izračunate prema algoritmu TLOVR (TLOVR = vrijeme do gubitka virološkog odgovora)
English: Patients co-infected with hepatitis B and/or hepatitis C virus In the pooled analysis for DUET-1 and DUET-2, the incidence of hepatic events tended to be higher in co-infected subjects treated with etravirine compared to co-infected subjects in the placebo group.
Croatian: Bolesnici istodobno zaraženi virusom hepatitisa B i/ili hepatitisa C U analizi udruženih podataka iz ispitivanja DUET-1 i DUET-2, incidencija nuspojava vezanih uz jetru bila je viša u ispitanika istodobno zaraženih virusom hepatitisa B i hepatitisa C liječenih etravirinom nego u skupini istodobno zaraženih ispitanika u skupini koja je primala placebo.
English: - If you are unable to swallow the INTELENCE tablet(s) whole, you may do the following: place the tablet(s) in 5 ml (1 teaspoon) of water, or at least enough liquid to cover the medicine, stir well until the water looks milky, if desired, add more water or alternatively orange juice or milk (do not place the tablets directly in orange juice or milk), drink it immediately, rinse the glass several times with water, orange juice, or milk and completely swallow the rinse each time to make sure you take the entire dose.
Croatian: - Ako ne možete progutati cijele tabletu(e) lijeka INTELENCE, možete napraviti sljedeće: tabletu(e) možete staviti u 5 ml (1 čajnu žličicu) vode, ili barem dovoljno tekućine da pokrije lijek, dobro promiješajte dok voda ne poprimi mliječni izgled, ako želite, dodajte još vode ili alternativno sok od naranče ili mlijeko (nemojte staviti tablete u sok od naranče ili mlijeko), odmah ju popijte, isperite čašu nekoliko puta s vodom, sokom od naranče ili mlijekom i svaki put popijte cijeli sadržaj do kraja kako biste bili sigurni da ste uzeli cijelu dozu.
English: HIV Protease Inhibitors (PIs) - Unboosted (i.e. without co-administration of low-dose ritonavir) Indinavir
Croatian: Inhibitori proteaze (IP) HIV-a - nepojačani (tj. bez istovremene primjene niske doze ritonavira) Indinavir
English: No significant effect on didanosine and etravirine PK parameters is seen.
Croatian: Nije opažen značajni učinak na farmakokinetičke parametre didanozina i etravirina.
English: 6 cells/l
Croatian: 6 stanica/l
English: Cmax ↑ 1.76 (1.60-1.94) etravirine
Croatian: Cmax ↑ 1,76 (1,60-1,94) etravirin
English: - Tell your doctor if you have or have had problems with your liver, including hepatitis B and/or C. Your doctor may evaluate how severe your liver disease is before deciding if you can take INTELENCE.
Croatian: - Upozorite svog liječnika ako imate ili ste prije imali probleme s jetrom uključujući hepatitis B i/ili C.
English: Skin and subcutaneous tissue disorders very common rash common night sweats, dry skin, prurigo uncommon angioneurotic oedema a, swelling face, hyperhidrosis rare
Croatian: Poremećaji kože i potkožnog tkiva vrlo često osip često noćna znojenja, suha koža, prurigo manje često angioneurotski edem a, oticanje lica, hiperhidroza rijetko
English: Co-administration of etravirine with elbasvir/grazoprevir may decrease elbasvir and grazoprevir concentrations, leading to reduced therapeutic effect of elbasvir/grazoprevir.
Croatian: Istodobna primjena etravirina s elbasvirom/grazoprevirom može sniziti koncentracije elbasvira i grazoprevira, što dovodi do smanjenog terapijskog učinka elbasvira/grazoprevira.
English: Paediatric population (6 years to less than 18 years of age) The pharmacokinetics of etravirine in 101 treatment-experienced HIV-1 infected paediatric patients, 6 years to less than 18 years of age and weighing at least 16 kg, showed that the administered weight-based dosages resulted in etravirine exposure comparable to that in adults receiving etravirine 200 mg twice daily (see sections 4.2 and 5.2) when administered at a dose corresponding to 5.2 mg/kg twice daily.
Croatian: Pedijatrijska populacija (u dobi od 6 godina do manje od 18 godina) Farmakokinetika etravirina u 101 bolesnika zaraženog HIVom-1, koji su prethodno liječeni antiretrovirusnim lijekovima, u dobi od 6 godina do manje od 18 godina i težine barem 16 kg, pokazala je usporedive rezultate za izloženost etravirinu za dozu primijenjenu na temelju težine, u dozi koja odgovara 5,2 mg/kg dva puta dnevno u odnosu na odrasle koji primaju etravirin 200 mg dva puta dnevno (vidjeti dijelove 4.2 i 5.2).
English: In HIV infected patients with severe immune deficiency at the time of initiation of CART, an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Croatian: U bolesnika zaraženih HIV-om s teškom imunodeficijencijom u vrijeme započinjanja kombinirane antiretrovirusne terapije (KART) može doći do upalne reakcije na asimptomatske ili rezidualne oportunističke patogene, koja može uzrokovati teška klinička stanja ili pogoršanje simptoma.
English: Bone problems
Croatian: Problemi s kostima
English: Table 8: Population pharmacokinetic estimates for etravirine (all doses combined) in treatment-experienced HIV-1 infected paediatric patients 6 years to less than 18 years of age (PIANO 48 week analysis)
Croatian: Tablica 8: Populacijska farmakokinetička procjena za etravirin (kombinirano za sve doze) u pedijatrijskih ispitanika zaraženih HIVom-1 koji su prethodno liječeni antiretrovirusnim lijekovima, u dobi od 6 godina do manje od 18 godina (analiza podataka ispitivanja PIANO u 48. tjednu)
English: Concomitant systemic use of itraconazole or ketoconazole and etravirine may increase plasma concentrations of etravirine.
Croatian: Istodobna sistemska primjena itrakonazola ili ketokonazola i etravirina može povećati koncentracije etravirina u plazmi.
English: Etravirine exhibits activity against wild type HIV-1 in T-cell lines and primary cells with median EC50 values ranging from 0.9 to 5.5 nM. Etravirine demonstrates activity against HIV-1 group M (subtypes A, B, C, D, E, F, and G) and HIV-1 group O primary isolates with EC50 values ranging from 0.3 to 1.7 nM and from 11.5 to 21.7 nM, respectively.
Croatian: Etravirin pokazuje aktivnost protiv primarnog izolata HIV-1 iz skupine M (podtipovi A, B, C, D, E, F i G) uz vrijednosti EC50 u rasponu od 0,3 do 1,7 nM, i primarnog izolata HIV-1 iz skupine O uz vrijednosti EC50 u rasponu od 11,5 do 21,7 nM.
English: Metabolism and nutrition disorders common diabetes mellitus, hyperglycaemia, hypercholesterolaemia, increased low density lipoprotein (LDL), hypertriglyceridaemia, hyperlipidaemia, dyslipidaemia, anorexia
Croatian: Poremećaji metabolizma i prehrane često dijabetes melitus, hiperglikemija, hiperkolesterolemija, povišen lipoprotein niske gustoće (LDL), hipertrigliceridemija, hiperlipidemija, dislipidemija, anoreksija
English: Not de novo ENF
Croatian: Nije de novo ENF
English: Geometric Mean ± Standard Deviation Median (Range)
Croatian: Geometrijska srednja vrijednost ± standardna devijacija
English: Dolutegravir + darunavir/ritonavir 50 mg once daily + 600/100 mg twice daily
Croatian: Dolutegravir + darunavir/ritonavir 50 mg jedanput dnevno + 600/100 mg dva puta dnevno
English: Rash was mostly self-limiting and generally resolved within 1 week on continued therapy.
Croatian: Osip je bio većinom samo-ograničavajući i općenito se povukao tijekom 1 tjedna na neprekinutoj terapiji.
English: Co-administration of etravirine with medicinal products primarily metabolised by CYP3A4 may result in decreased plasma concentrations of such medicinal products, which could decrease or shorten their therapeutic effects.
Croatian: Istovremena primjena etravirina s lijekovima koje primarno metabolizira izoenzim CYP3A4 može rezultirati smanjenom koncentracijom tih lijekova u plazmi, što bi moglo smanjiti ili skratiti njihove terapijske učinke.
English: Most often, rash was mild to moderate, of macular/papular type, and occurred in the second week of therapy.
Croatian: Osip je najčešće bio blag do umjeren, makularno/papularne vrste, i pojavio se u drugom tjednu liječenja.
English: Treatment-experienced paediatric patients (6 years to less than 18 years of age) PIANO is a single-arm, Phase II trial evaluating the pharmacokinetics, safety, tolerability, and efficacy of etravirine in 101 antiretroviral treatment-experienced HIV-1 infected paediatric patients 6 years to less than 18 years of age and weighing at least 16 kg.
Croatian: Prethodno liječeni pedijatrijski bolesnici (u dobi od 6 do manje od 18 godina) PIANO je ispitivanje faze II s jednom skupinom, u kojem je procijenjena farmakokinetika, sigurnost, podnošljivost i djelotvornost etravirina u 101 pedijatrijskog bolesnika zaraženog HIVom-1, u dobi od 6 do manje od 18 godina i težine najmanje 16 kg, koji je prethodno liječen antiretrovirusnim lijekovima.
English: Etravirine (200 mg twice daily), evaluated in combination with other antiretroviral medicinal products in a study of 15 pregnant women during the second and third trimesters of pregnancy and postpartum, demonstrated that exposure to total etravirine was generally higher during pregnancy compared with postpartum, and less so for unbound etravirine exposure (see section 5.2).
Croatian: U ispitivanju s 15 trudnica, procijenjen je etravirin (200 mg dva puta dnevno) u kombinaciji s drugim antiretrovirusnim lijekovima tijekom drugog i trećeg tromjesečja trudnoće i postpartalnog razdoblja, pri čemu se pokazalo da je izloženost ukupnom etravirinu općenito veća tijekom trudnoće u odnosu na postpartalno razdoblje, što se manje pokazalo za izloženost nevezanom etravirinu (vidjeti dio 5.2).
English: Etravirine significantly reduced plasma concentrations of dolutegravir.
Croatian: Etravirin je značajno smanjio koncentracije dolutegravira u plazmi.
English: The safety and efficacy of etravirine in children less than 6 years of age and weighing less than 16 kg have not yet been established (see section 5.2).
Croatian: Pedijatrijska populacija (u dobi manje od 6 godina) Sigurnost i djelotvornost etravirina u djece mlađe od 6 godina i težine manje od 16 kg nisu još ustanovljene (vidjeti dio 5.2).
English: The combination of oestrogen- and/or progesterone-based contraceptives and INTELENCE can be used without dose adjustment.
Croatian: Kombinaciju kontracepcijskih sredstava na bazi estrogena i/ili progesterona i INTELENCE može se koristiti bez prilagodbe doze.
English: If the patient misses a dose of INTELENCE within 6 hours of the time it is usually taken, the patient should take it following a meal as soon as possible and then take the next dose at the regularly scheduled time.
Croatian: U slučaju da bolesnik propusti dozu lijeka INTELENCE unutar 6 sati od njenog uobičajenog vremena uzimanja, bolesnik ju mora uzeti čim prije nakon obroka, a potom sljedeću dozu treba uzeti u uobičajeno vrijeme uzimanja.
English: Imputations according to the TLOVR algorithm (TLOVR = Time to Loss of Virologic Response).
Croatian: Pripisane vrijednosti izračunate prema algoritmu TLOVR (TLOVR = vrijeme do gubitka virološkog odgovora).
English: INTELENCE can be co-administered with proton pump inhibitors without dose adjustments.
Croatian: INTELENCE se može primjenjivati istodobno s inhibitorima protonske pumpe bez prilagodbe doze.
English: If a patient vomits within 4 hours of taking the medicine, another dose of INTELENCE should be taken following a meal as soon as possible.
Croatian: Ako bolesnik povraća unutar 4 sata od uzimanja lijeka, potrebno je što prije uzeti drugu dozu lijeka INTELENCE nakon obroka.
English: INTELENCE has not been studied in patients with severe hepatic impairment (Child-Pugh Class C) and is therefore not recommended (see sections 4.2 and 4.4).
Croatian: INTELENCE nije ispitan kod bolesnika s teškim oštećenjem jetre (Child-Pugh stadij C) i stoga se ne preporučuje (vidjeti dio 4.2 i
English: Etravirine is expected to decrease plasma concentrations of cyclosporine, sirolimus and tacrolimus.
Croatian: Očekuje se da će etravirin smanjiti koncentracije ciklosporina, sirolimusa i takrolimusa u plazmi.
English: ≥ 1 log10 decrease from baseline at week 24, n (%)
Croatian: ≥ 1 log10 pad u odnosu na početnu vrijednost u 24. tjednu, n (%)
English: 40 mg once daily etravirine
Croatian: 40 mg jedanput dnevno etravirin
English: Viral load < 400 copies/ml at week 24, n (%)
Croatian: Virusno opterećenje < 400 kopija/ml u 24. tjednu, n (%)
English: Carbazamepine, phenobarbital and phenytoin are expected to decrease plasma concentrations of etravirine.
Croatian: Očekuje se da karbazamepin, fenobarbital i fenitoin smanjuju koncentraciju etravirina u plazmi.
English: It is not recommended to co-administer INTELENCE with indinavir.
Croatian: Ne preporučuje se istodobno primjenjivati INTELENCE i indinavir.
English: Severe cutaneous adverse reactions have been reported with etravirine.
Croatian: Prijavljene su teške kožne nuspojave s etravirinom.
English: INTELENCE 25 mg tablets INTELENCE 100 mg tablets INTELENCE 200 mg tablets
Croatian: INTELENCE 25 mg tablete INTELENCE 100 mg tablete INTELENCE 200 mg tablete
English: Etravirine 200 mg twice daily N = 575
Croatian: Etravirin 200 mg dva puta dnevno N = 575
English: The mean change in plasma HIV-1 RNA from baseline to week 48 was -1.53 log10 copies/ml, and the mean CD4 cell count increase from baseline was 156 x 10
Croatian: Srednja promjena vrijednosti u odnosu na početnu vrijednost HIV-1 RNK u plazmi do 48. tjedna bila je -1,53 log10 kopija/ml, a porast u odnosu na početnu vrijednost srednje vrijednosti broja CD4 stanica bio je 156 x 10
English: In the Phase III trials DUET-1 and DUET-2, mutations that developed most commonly in patients with virologic failure to the etravirine containing regimen were V108I, V179F, V179I, Y181C and Y181I, which usually emerged in a background of multiple other NNRTI resistance-associated mutations (RAMs).
Croatian: U kliničkim ispitivanjima faze III DUET-1 i DUET-2 mutacije koje su se najčešće razvile u bolesnika s neuspjelim virološkim odgovorom na način liječenja etravirinom bile su V108I, V179F, V179I, Y181C i Y181I i obično su se pojavljivale u pozadini višestrukih drugih NNRTI mutacija povezanih s rezistencijom (RAM).
English: TMC125-C213 6 to < 12 years ETR N = 41
Croatian: TMC125-C213 6 do < 12 godina ETR N = 41
English: ANTIMALARIALS Artemether/ Lumefantrine 80/480 mg, 6 doses at 0, 8, 24, 36, 48, and 60 hours artemether
Croatian: 80/480 mg, 6 doza u 0., 8., 24., 36., 48. i
English: This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium free'.
Croatian: Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po tableti, tj. zanemarive količine natrija.
English: Most frequently, rash was mild to moderate, occurred in the second week of therapy, and was infrequent after week 4.
Croatian: Najčešće je osip bio blag do umjeren, pojavio se u drugom tjednu liječenja, a nakon 4 tjedna bio je rijedak.
English: Manufacturer Janssen-Cilag SpA, Via C. Janssen, 04100 Borgo San Michele, Latina, Italy
Croatian: Janssen, 04100 Borgo San Michele, Latina, Italija
English: Baseline genotype or phenotype and virologic outcome analyses In DUET-1 and DUET-2, the presence at baseline of 3 or more of the following mutations: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A and G190S, (etravirine RAMs) was associated with a decreased virologic response to etravirine (see table 5).
Croatian: Početni genotip ili fenotip i analize virološkog ishoda U ispitivanjima DUET-1 i DUET-2, prisutnost 3 ili više sljedećih mutacija: V90I, A98G, L100I, K101E, K101P, V106I, V179D, V179F, Y181C, Y181I, Y181V, G190A i G190S, (etravirin RAMs) na početku, bila je povezana sa smanjenim virološkim odgovorom na etravirin (vidjeti tablicu 5).
English: Psychiatric disorders common anxiety, insomnia, sleep disorders uncommon confusional state, disorientation, nightmares,
Croatian: Psihijatrijski poremećaji često anksioznost, nesanica, poremećaji spavanja manje često stanje smetenosti, dezorijentiranost, noćne more, nervoza, abnormalni snovi